HURA

TuHURA Biosciences Inc

Add to Watchlist

Advanced Chart

2.300

-0.13(-5.350%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.4623

Open

2.430

VWAP

2.38

Vol

134.28K

Mkt Cap

107.06M

Low

2.290

Amount

319.73K

EV/EBITDA(TTM)

Total Shares

46.55M

107.17M

EV/OCF(TTM)

P/S(TTM)

TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.

3 Analyst Rating

421.74% Upside

Wall Street analysts forecast HURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HURA is 12.00 USD with a low forecast of 9.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

421.74% Upside

Current: 2.300

Low

9.00

Averages

12.00

High

15.00

421.74% Upside

Current: 2.300

Low

9.00

Averages

12.00

High

15.00

Brookline

NULL

Buy

initiated

2025-06-23

Reason

Brookline

Price Target

2025-06-23

initiated

NULL

Buy

Reason

Brookline initiated coverage of TuHURA Biosciences with a Buy rating and $9 price target. TuHURA Biosciences is advancing innate immune agonists, checkpoint inhibitors, and antibody-drug conjugates to overcome checkpoint inhibitor resistance and to modulate tumor microenvironment, the analyst tells investors in a research note. The firm sees a favorable risk-reward as IFx-2.0 advances through the clinic, saying there is a significant unmet need for treatments to overcome CPI resistance in Merkel cell carcinoma.

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$13 → $12

2025-04-03

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$13 → $12

2025-04-03

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Initiates

$13

2025-03-03

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$13

2025-03-03

Initiates

Strong Buy

Reason

Rodman & Renshaw

Tony Butler

Strong Buy

Initiates

$11

2024-12-19

Reason

Rodman & Renshaw

Tony Butler

Price Target

$11

2024-12-19

Initiates

Strong Buy

Reason

Rodman & Renshaw initiated coverage of TuHURA Biosciences with a Buy rating and $11 price target. TuHURA is focused on developing treatments to overcome primary and acquired resistance to checkpoint inhibitors by using its proprietary technology platform, Immune FxTM, the analyst tells investors in a research note. The firm says the company's strategy leverages bacterial proteins to activate the immune system avoids common issues like the toxicity and infections often linked to using attenuated bacteria for cancer therapy.

See All Ratings

Valuation Metrics

The current forward P/E ratio for TuHURA Biosciences Inc (HURA.O) is -4.54, compared to its 5-year average forward P/E of -8.10. For a more detailed relative valuation and DCF analysis to assess TuHURA Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.10

Current PE

-4.54

Overvalued PE

-4.65

Undervalued PE

-11.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q1

YoY :

+128.38%

-6.76M

Operating Profit

FY2025Q1

YoY :

+125.00%

-6.66M

Net Income after Tax

FY2025Q1

YoY :

-99.77%

-0.15

EPS - Diluted

FY2025Q1

YoY :

+263.03%

-4.78M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

206.0K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

16.0K

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

HURA News & Events

Events Timeline

2025-07-01 (ET)

2025-07-01

08:53:46

TuHURA Biosciences included in Russell 3000 and 2000 Indexes

2025-06-24 (ET)

2025-06-24

08:04:58

TuHURA Biosciences initiates Phase 3 approval trial of IFx-2.0 in carcinoma

2025-06-23 (ET)

2025-06-23

17:03:00

TuHURA Biosciences, Kineta stockholders approve merger and related proposals

News

3.5

07-01Newsfilter

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

8.5

06-30Newsfilter

TuHURA Biosciences Completes Acquisition of Kineta

9.0

06-24PRnewswire

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma